EMA's trial design hinders Eisai's Halaven reimbursement in Germany
This article was originally published in Scrip
Executive Summary
Eisai's end of life breast cancer drug Halaven (eribulin) offers a "hint" of "unquantifiable" additional benefit against comparators for patients unable to continue treatment with taxanes or anthracyclines, according to a preliminary benefit assessment by the German health technology appraisal body, IQWiG. Furthermore, the drug offers no additional benefit for patients able to continue with taxanes or anthracyclines, said the institute.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.